Kentucky Retirement Systems Insurance Trust Fund Acquires Shares of 2,363 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,363 shares of the company's stock, valued at approximately $992,000.

Other institutional investors have also bought and sold shares of the company. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter worth about $29,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter worth about $30,000. Colonial Trust Co SC boosted its position in shares of IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares in the last quarter. Itau Unibanco Holding S.A. boosted its position in shares of IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Finally, Retirement Wealth Solutions LLC boosted its position in shares of IDEXX Laboratories by 40.0% during the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock worth $44,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Down 0.0%

NASDAQ IDXX traded down $0.10 during trading hours on Wednesday, hitting $530.40. The company's stock had a trading volume of 520,377 shares, compared to its average volume of 644,932. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $533.32. The company has a market capitalization of $42.66 billion, a PE ratio of 49.02, a price-to-earnings-growth ratio of 3.87 and a beta of 1.55. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. The company's 50-day simple moving average is $494.30 and its two-hundred day simple moving average is $449.63.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same quarter last year, the firm earned $2.71 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Leerink Partners increased their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $546.00.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director now owns 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.